Mission To create transformative therapies that improve lives of people living with genetic diseases.
Description Castle Creek Biosciences, Inc., is a late-stage company developing re-dosable gene therapies. It is launching a pivotal clinical trial of its lead candidate, D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).